Letter to the editor: Overlooking the important factor: Hypoxia
Yusheng Guo, Yanqiao Ren, Xiangjun Dong, Xuefeng Kan, Chuansheng Zheng – 2 August 2022
The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression
Irene Peñuelas‐Haro, Rut Espinosa‐Sotelo, Eva Crosas‐Molist, Macarena Herranz‐Itúrbide, Daniel Caballero‐Díaz, Ania Alay, Xavier Solé, Emilio Ramos, Teresa Serrano, María L. Martínez‐Chantar, Ulla G. Knaus, José M. Cuezva, Antonio Zorzano, Esther Bertran, Isabel Fabregat – 2 August 2022
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression
María Juárez‐Fernández, Naroa Goikoetxea‐Usandizaga, David Porras, María Victoria García‐Mediavilla, Miren Bravo, Marina Serrano‐Maciá, Jorge Simón, Teresa C. Delgado, Sofía Lachiondo‐Ortega, Susana Martínez‐Flórez, Óscar Lorenzo, Mercedes Rincón, Marta Varela‐Rey, Leticia Abecia, Héctor Rodríguez, Juan Anguita, Esther Nistal, María Luz Martínez‐Chantar, Sonia Sánchez‐Campos – 2 August 2022
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3
Kristy St. Rose, Jun Yan, Fangxi Xu, Jasmine Williams, Virginia Dweck, Deepak Saxena, Robert F. Schwabe, Jorge Matias Caviglia – 2 August 2022 – Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and the world; with no Food and Drug Administration–approved pharmacological treatment available, it remains an area of unmet medical need. In nonalcoholic steatohepatitis (NASH), the most important predictor of clinical outcome is the fibrosis stage.
Letter to the editor: Successful treatment of multidrug‐resistant hepatis C after >12 months of continuous therapy with direct‐acting antivirals
Wenhao Luo, Ying Zhang, Taiping Zhang – 2 August 2022
Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation‐driven hepatocarcinogenesis
Binyong Liang, Haichuan Wang, Yu Qiao, Xue Wang, Manning Qian, Xinhua Song, Yi Zhou, Yi Zhang, Runze Shang, Li Che, Yifa Chen, Zhiyong Huang, Hong Wu, Satdarshan P. Monga, Yong Zeng, Diego F. Calvisi, Xiaoping Chen, Xin Chen – 2 August 2022
Letter to the editor: Cautious interpretation of the compensation of insulin‐mTORC1 activation to promote liver regeneration in the absence of hepatocyte β‐catenin
Cong Ning, Xin‐Mu Zhang, Xin‐Ting Sang, Hai‐Tao Zhao – 1 August 2022
“Long‐term” is getting longer for children receiving liver transplantation grafts
Pamela L. Valentino – 31 July 2022
Waitlist mortality in pediatric liver transplantation: The goal is zero
George V. Mazariegos, Kyle A. Soltys, Emily R. Perito – 31 July 2022
A new approach to manage aberrant hepatic arteries in liver transplantation: Is one better than two?
Quirino Lai, Jan Lerut – 30 July 2022